Anti-CD4 monoclonal antibody-induced allograft survival is associated with a defect in interleukin-2-dependent T-cell activation.
Pearson
T C
TC
Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Headington, UK.
Hamano
K
K
Morris
P J
PJ
Wood
K J
KJ
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015704:CD4 Antigens / Q000276:immunology*; D006085:Graft Survival / Q000276:immunology*; D016027:Heart Transplantation / Q000276:immunology*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology*; D008213:Lymphocyte Activation; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D011994:Recombinant Proteins / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D011994:Recombinant Proteins